ITRACONAZOLE ( DrugBank: Itraconazole )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
3	脊髄性筋萎縮症	1
65	原発性免疫不全症候群	1
96	クローン病	1
227	オスラー病	1
299	嚢胞性線維症	5

3. 脊髄性筋萎縮症

臨床試験数 : 217 / 薬物数 : 149 - (DrugBank : 33) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 80

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02633709 (ClinicalTrials.gov)	January 7, 2016	15/12/2015	A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers	A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects	Spinal Muscular Atrophy	Drug: Itraconazole;Other: Placebo;Drug: Risdiplam	Hoffmann-La Roche	NULL	Completed	18 Years	45 Years	Male	33	Phase 1	Netherlands

65. 原発性免疫不全症候群

臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00001280 (ClinicalTrials.gov)	January 1991	3/11/1999	Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease	Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease	Mycoses	Drug: itraconazole	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	N/A	N/A	Both	100	Phase 2	United States

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05049525 (ClinicalTrials.gov)	January 2022	25/8/2021	Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease	Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current Therapy	Crohn's Disease;Inflammatory Bowel Diseases	Drug: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.;Drug: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.	Montreal Heart Institute	NULL	Not yet recruiting	18 Years	65 Years	All	68	Phase 2	NULL

227. オスラー病

臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-003272-31-NL (EUCTR)	18/05/2018	11/01/2018	Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasia	Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients	Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850 MedDRA version: 20.0;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Sporanox Product Name: Itraconazole	St. Antonius Ziekenhuis	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	25	Phase 2	Netherlands

299. 嚢胞性線維症

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01576315 (ClinicalTrials.gov)	June 2014	29/3/2012	ATCF (Azole Therapy in Cystic Fibrosis)	Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus.	Cystic Fibrosis;Aspergillus Infections	Drug: Itraconazole/voriconazole	Rennes University Hospital	NULL	Completed	12 Years	N/A	Both	11	Phase 2	France;United Kingdom
2	NCT01768663 (ClinicalTrials.gov)	January 2013	11/1/2013	A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects	A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects	Cystic Fibrosis	Drug: Lumacaftor;Drug: Ivacaftor;Drug: Ciprofloxacin;Drug: Itraconazole;Drug: Rifampin	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	55 Years	Both	80	Phase 1	United States
3	EUCTR2011-005799-41-GB (EUCTR)	04/10/2012	21/08/2012	Azole Therapy in Cystic Fibrosis (ATCF)	Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and ofvoriconazole in patients with cystic fibrosis and presenting withpersistent positive sputums for Aspergillus - Azole Therapy in Cystic Fibrosis (ATCF)	Cystic fibrosis MedDRA version: 14.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.1;Level: HLT;Classification code 10003486;Term: Aspergillus infections;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: SPORANOX Product Name: Sporanox 10 mg/ml Oral Solution INN or Proposed INN: ITRACONAZOLE Other descriptive name: SPORANOX Trade Name: V-Fend Product Name: VFEND 40 mg/ml powder for oral suspension INN or Proposed INN: voriconazole Other descriptive name: Vfend	CHU de Rennes (Rennes University Hospital Centre)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150		United Kingdom
4	NCT00787917 (ClinicalTrials.gov)	November 2008	7/11/2008	An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)	An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)	Cystic Fibrosis;Allergic Bronchopulmonary Aspergillosis	Drug: Omalizumab;Drug: Placebo;Drug: Itraconazole	Novartis Pharmaceuticals	NULL	Terminated	12 Years	N/A	All	14	Phase 4	Belgium;Germany;Italy;Netherlands;United Kingdom
5	NCT00528190 (ClinicalTrials.gov)	October 2007	10/9/2007	Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis	Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial	Cystic Fibrosis	Drug: Itraconazole	Ottawa Hospital Research Institute	The Hospital for Sick Children;Canadian Cystic Fibrosis Foundation;The Physicians' Services Incorporated Foundation	Completed	6 Years	N/A	All	35	Phase 4	Canada

先頭へ